DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300

被引:9
作者
Kim, Hwa Jin [1 ,2 ]
Moon, Sue Jin [1 ,2 ]
Hong, Sanghoon [3 ]
Won, Hong-Hee [2 ,3 ]
Kim, Jeong Hoon [1 ,2 ]
机构
[1] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 06351, South Korea
[2] Samsung Med Ctr, Res Inst Future Med, Seoul 06351, South Korea
[3] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Digital Hlth, Seoul 06351, South Korea
基金
新加坡国家研究基金会;
关键词
TRANSCRIPTION; CANCER; ACTIVATION; ACETYLATION; PROGRESSION; INHIBITION; PROMOTERS; MLL3/MLL4; BINDING; DOMAIN;
D O I
10.1093/nar/gkac585
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone modification is a key epigenetic mechanism for regulation of chromatin dynamics and gene expression. Deleted in breast cancer 1 (DBC1) has been shown to act as a negative regulator of epigenetic modifiers and as a co-activator for nuclear receptors and other transcription factors. However, little is known about the role of DBC1 in the regulation of histone modifications and chromatin landscapes. Here, we analyzed genome-wide profiles of active enhancer and promoter marks in colorectal cancer cells and report DBC1 as a critical positive regulator of histone epigenetic writers KMT2D (H3K4 methyltransferase) and p300 (histone acetyltransferase). DBC1 is required for establishing the landscape of active enhancers, for genome-wide chromatin binding and enhancer recruitment of KMT2D and p300, and for gene activation involved in colorectal cancer progression. DBC1 interacts directly with KMT2D and p300, and enhances KMT2D-mediated histone H3K4 methylation (H3K4me1/2/3) and p300-mediated H3 acetylation. Importantly, DBC1 contributes to super-enhancer formation and function by facilitating the recruitment of KMT2D and p300 and by enhancing their functional interaction and cooperative cross-talk. Our results highlight the critical role of DBC1 as a key positive regulator of KMT2D and p300, and provide insights into regulatory mechanisms underlying the interplay between the enhancer epigenomic writers in enhancer activation.
引用
收藏
页码:7873 / 7888
页数:16
相关论文
共 45 条
[21]   MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis [J].
Lai, Binbin ;
Lee, Ji-Eun ;
Jang, Younghoon ;
Wang, Lifeng ;
Peng, Weiqun ;
Ge, Kai .
NUCLEIC ACIDS RESEARCH, 2017, 45 (11) :6388-6403
[22]   KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies [J].
Lavery, William J. ;
Barski, Artem ;
Wiley, Susan ;
Schorry, Elizabeth K. ;
Lindsley, Andrew W. .
CLINICAL EPIGENETICS, 2020, 12 (01)
[23]   H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation [J].
Lee, Ji-Eun ;
Wang, Chaochen ;
Xu, Shiliyang ;
Cho, Young-Wook ;
Wang, Lifeng ;
Feng, Xuesong ;
Baldridge, Anne ;
Sartorelli, Vittorio ;
Zhuang, Lenan ;
Peng, Weiqun ;
Ge, Kai .
ELIFE, 2013, 2
[24]   Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance [J].
Li, Guo-Hua ;
Qu, Qiang ;
Qi, Ting-Ting ;
Teng, Xin-Qi ;
Zhu, Hai-Hong ;
Wang, Jiao-Jiao ;
Lu, Qiong ;
Qu, Jian .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
[25]   Inhibition of SUV39H1 Methyltransferase Activity by DBC1 [J].
Li, Zhenyu ;
Chen, Lihong ;
Kabra, Neha ;
Wang, Chuangui ;
Fang, Jia ;
Chen, Jiandong .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (16) :10361-10366
[26]   Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers [J].
Loven, Jakob ;
Hoke, Heather A. ;
Lin, Charles Y. ;
Lau, Ashley ;
Orlando, David A. ;
Vakoc, Christopher R. ;
Bradner, James E. ;
Lee, Tong Ihn ;
Young, Richard A. .
CELL, 2013, 153 (02) :320-334
[27]   Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes [J].
Messier, Terri L. ;
Gordon, Jonathan A. R. ;
Boyd, Joseph R. ;
Tye, Coralee E. ;
Browne, Gillian ;
Stein, Janet L. ;
Lian, Jane B. ;
Stein, Gary S. .
ONCOTARGET, 2016, 7 (05) :5094-5109
[28]   Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer [J].
Moon, Sue Jin ;
Jeong, Byong Chang ;
Kim, Hwa Jin ;
Lim, Joung Eun ;
Kim, Hye-Jeong ;
Kwon, Ghee Young ;
Jackman, Joshua A. ;
Kim, Jeong Hoon .
THERANOSTICS, 2021, 11 (02) :958-973
[29]   DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7 [J].
Moon, Sue Jin ;
Jeong, Byong Chang ;
Kim, Hwa Jin ;
Lim, Joung Eun ;
Kwon, Ghee Young ;
Kim, Jeong Hoon .
ONCOGENE, 2018, 37 (10) :1326-1339
[30]   Transcription factor PROM induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype [J].
Petrova, Tatiana V. ;
Nykanen, Antti ;
Norrmen, Camilla ;
Ivanov, Konstantin I. ;
Andersson, Leif C. ;
Haglund, Caj ;
Puolakkainen, Pauli ;
Wempe, Frank ;
von Melchner, Harald ;
Gradwohl, Gerard ;
Vanharanta, Sakari ;
Aaltonen, Lauri A. ;
Saharinen, Juha ;
Gentile, Massimiliano ;
Clarke, Alan ;
Taipale, Jussi ;
Oliver, Guillermo ;
Alitalo, Kari .
CANCER CELL, 2008, 13 (05) :407-419